

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/533,798	03/24/2000	Miles William Carroll	078883/0120 2448		
7	7590 10/02/2002				
Bernhard D Saxe Foley & Lardner Washington Harbour 3000 K Street N W Suite 500 Washington, DC 20007-5109			EXAMINER		
			SCHEINER, LAURIE A		
			ART UNIT	PAPER NUMBER	
···			1648		
			DATE MAILED: 10/02/2002 /O		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application N	No.	Applicant(s)			
Office Action Summary		09/533,798		CARROLL ET AL.			
		Examiner		Art Unit			
		Laurie Scheir	ner	1648			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status 1)⊠	_						
2a)□	This action is FINAL . 2b) This action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Dispositi	Disposition of Claims						
4)⊠ Claim(s) <u>1-4,6,8-16,18-34 and 41-45</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6)□	Claim(s) is/are rejected.						
•	Claim(s) is/are objected to.						
•	Claim(s) <u>1-4,6,8-16,18-34,41-45</u> are subject to	restriction and	d/or election require	ment.			
	on Papers						
•	The specification is objected to by the Examine		ested to by the Ever	ninor			
10)	The drawing(s) filed on is/are: a)☐ acception Applicant may not request that any objection to the						
11\\	• • • • • • • • • • • • • • • • • • • •						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a) The translation of the foreign language provisional application has been received.							
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	4) 5) 6)	Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)			

Art Unit: 1648

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-4, and 31, drawn to a viral vector expressing 5T4 antigen, classified in class 435, subclass 320.1.
- II. Claims 6 and 8, drawn to a modified antigen, classified in class 530, subclass 328.
- III. Claims 9-12, 14, and 16, drawn to a vaccine comprising 5T4, classified in class 424, subclass 277.1.
- IV. Claims 13, 15, 18-21, drawn to a method of eliciting an immune response against 5T4 in a subject, classified in class 514, subclass 44.
 - V. Claims 24-30 and 43, drawn to a vector encoding a TAA, classified in class 435, subclass 320.1.
 - VI. Claims 32-34 and 41, drawn to a method of eliciting an immune response by administering a vector encoding a TAA, classified in class 424, subclass 277.1.
 - VII. Claim 42, drawn to a method of breaking immune tolerance by administering a poxvirus encoding a weak immunogen, classified in class 424, subclass 184.1.
 - VIII. Claims 22 and 44, drawn to a kit comprising a vector encoding a fused molecule, classified in class 536, subclass 23.4 and class 514, subclass 1.11.
 - IX. Claims 23 and 45, drawn to a kit comprising a vector and a prodrug/enzyme, classified in class 536, subclass 23.2 and 23.4.

The inventions are distinct, each from the other because of the following reasons:

Art Unit: 1648

Inventions I and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, although the different inventions comprise vectors, each vector expresses a structurally and functionally distinct tumor antigen. The vector of group V can be used to express a number if various tumor products.

Inventions I, II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the antigen of group III does not require a vector and is chemically and functionally distinct from either group I or II.

Inventions I, III and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the method can be practiced with either product of group I or III.

Inventions V and VI are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP

Art Unit: 1648

§ 806.05(h)). In the instant case the vector of group V can be used in different processes, such as transfecting a cell culture to produce TAA proteins.

Inventions VIII and IX are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to different kits comprising different components that can be used in different methods.

Inventions I-VI, VIII, IX and VII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions the method of group VII requires different steps and ingredients from any of the methods in previous groups and does not require the use of any of the claimed products.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the

Art Unit: 1648

application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Laurie Scheiner whose telephone number is (703) 308-1122. The examiner can normally be reached on M-F 9:00-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on (703) 308-4027. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-4426 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Laurie Scheiner September 30, 2002

RVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600